Get the Stockscreener App
28.59
2.19%
-0.64
After Hours:
28.59
Crinetics Pharmaceuticals Inc stock is traded at $28.59, with a volume of 718.83K.
It is down -2.19% in the last 24 hours and down -0.59% over the past month.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
See More
Previous Close:
$29.23
Open:
$28.81
24h Volume:
718.83K
Relative Volume:
0.92
Market Cap:
$2.68B
Revenue:
$4.72M
Net Income/Loss:
$-277.91M
P/E Ratio:
-7.6649
EPS:
-3.73
Net Cash Flow:
$-203.56M
1W Performance:
-5.98%
1M Performance:
-0.59%
6M Performance:
-29.06%
1Y Performance:
-46.18%
1-Day Range:
$28.45
$29.55
1-Week Range:
$28.45
$31.50
52-Week Range:
$24.10
$62.53
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Name
Crinetics Pharmaceuticals Inc
Sector
Industry
Phone
858-450-6464
Address
6055 LUSK BLVD., SAN DIEGO, CA
Compare CRNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
28.59 | 2.74B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Initiated | Goldman | Neutral |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-11-25 | Initiated | TD Cowen | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Peer Perform |
| Jan-22-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Jan-16-24 | Initiated | Morgan Stanley | Overweight |
| Dec-21-23 | Initiated | Jefferies | Hold |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-31-23 | Initiated | Oppenheimer | Outperform |
| Apr-24-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Robert W. Baird | Outperform |
| Nov-30-21 | Initiated | JMP Securities | Mkt Outperform |
| Nov-23-21 | Initiated | Evercore ISI | Outperform |
| Jun-18-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-23-19 | Initiated | ROTH Capital | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Aug-13-18 | Initiated | JP Morgan | Neutral |
| Aug-13-18 | Initiated | Leerink Partners | Outperform |
| Aug-13-18 | Initiated | Piper Jaffray | Overweight |
View All
Crinetics Pharmaceuticals Inc Stock (CRNX) Latest News
Crinetics Pharmaceuticals, Inc. (CRNX)’ Oral Acromegaly Drug Nears FDA Decision After Strong Phase 3 Data - MSN
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline - Yahoo Finance
11 Best Future Stocks to Buy Now - Insider Monkey
What makes Crinetics Pharmaceuticals Inc. stock price move sharplyCapital Preserving Trade Plan Templates Shared - metal.it
Why Crinetics Pharmaceuticals Inc. stock attracts strong analyst attentionLong Hold Safe Return Strategy Reviewed - metal.it
Can Crinetics Pharmaceuticals Inc. Bounce Back From Weekly LowSmart Investment Tips Gaining Popularity Among Analysts - metal.it
Analyzing net buyer seller activity in Crinetics Pharmaceuticals Inc.Steady Return Plan Based on Data Analysis - Newser
Using data filters to optimize entry into Crinetics Pharmaceuticals Inc.Technical Screener for High Growth Stocks - Newser
Pattern recognition hints at Crinetics Pharmaceuticals Inc. upsideConsistent Return Setup with Exit Strategy - Newser
How does Crinetics Pharmaceuticals Inc. compare to its industry peersInvest confidently with proven investment plans - jammulinksnews.com
Should I hold or sell Crinetics Pharmaceuticals Inc. stock in 2025Best Dividend Updates For Beginners - jammulinksnews.com
What institutional investors are buying Crinetics Pharmaceuticals Inc. stockUnlock your trading potential today - jammulinksnews.com
How strong is Crinetics Pharmaceuticals Inc. company’s balance sheetFind market-beating stocks for your portfolio - jammulinksnews.com
What are analysts’ price targets for Crinetics Pharmaceuticals Inc. in the next 12 monthsUnstoppable profit momentum - jammulinksnews.com
What catalysts could drive Crinetics Pharmaceuticals Inc. stock higher in 2025Capitalize on emerging market opportunities - jammulinksnews.com
Is Crinetics Pharmaceuticals Inc. a growth stock or a value stockExplosive capital appreciation - jammulinksnews.com
What are the technical indicators suggesting about Crinetics Pharmaceuticals Inc.Get timely alerts on market opportunities - jammulinksnews.com
Is it the right time to buy Crinetics Pharmaceuticals Inc. stockFree Stock Market Forecast Reports - jammulinksnews.com
Does Crinetics Pharmaceuticals Inc. stock perform well during market downturns - jammulinksnews.com
Is Crinetics Pharmaceuticals Inc. Stock Overbought or Oversold RSI Indicator Analysis2x 3x 5x Pick Alert - Newser
What drives Guess?, Inc. stock price? - jammulinksnews.com
Brokerages Set Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) PT at $69.50 - Defense World
Is Crinetics Pharmaceuticals Inc. a good long term investmentHigh-yield growth strategies - PrintWeekIndia
What analysts say about Crinetics Pharmaceuticals Inc. stockFree Investment Case Studies - PrintWeekIndia
Victory Capital Management Inc. Trims Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics’ 48% decline validates InvestingPro’s October 2024 overvalued call By Investing.com - Investing.com
Brokerages Set Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Price Target at $69.50 - Defense World
What drives Crinetics Pharmaceuticals Inc. stock priceAccelerated earnings growth - Autocar Professional
Crinetics Pharmaceuticals (CRNX) Gets Initiated With a Hold Rating at Goldman Sachs - MSN
Crinetics’ TSHR antagonist demonstrates efficacy in thyroid autoimmune disorders - BioWorld MedTech
Crinetics Pharmaceuticals Inc Stock (CRNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):